Summit's ivonescimab data has sparked interest in BioNTech's BNT327, and its potential to follow a similar path and gain value. Goldman incorporates risk-adjusted revenue forecasts that currently ...

BioNTech SE reported a surprise profit in the third quarter, helped by solid sales of its variant-adapted Covid-19 vaccines. Mainz, Germany-based BioNTech posted earnings of €0.81 ($0.88) per ...

Analysts' ratings for BioNTech (NASDAQ:BNTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The following table encapsulates their recent ratings, offering a ...

Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET) MAINZ, Germany, November 4, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the ...

BioNTech's Q3 revenue rose to €1.244 billion ($1.36 billion), driven by earlier COVID-19 vaccine approvals. Q3 net profit climbed to €198.1 million, with EPS increasing to 81 cents from 66 ...

In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

(RTTNews) - Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Monday a net profit of 198.1 million euros or 0.81 euros per share for the third quarter ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing varying results among patients. The hold impacts an open-label trial ...

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for covid, received its ...

German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327 ...

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma. The study is looking at ...